Granulocyte Colony-Stimulating Factor–Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease
Sumithira Vasu(The Ohio State University), Steven M. Devine(National Marrow Donor Program), Anissa Bingman(The Ohio State University), Rhonda Kitzler(The Ohio State University), Gerard Lozanski(The Ohio State University), Craig C. Hofmeister(The Ohio State University), Rebecca B. Klisovic(Goethe University Frankfurt), Leslie A. Andritsos(University of New Mexico), Sam Penza(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Yvonne A. Efebera(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Lynn O. Donnell(The Ohio State University), Samantha Jaglowski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jeffery J. Auletta(Nationwide Children's Hospital), Hillary Bradbury(The Ohio State University), Susan Geyer(University of South Florida), Pat Elder(The Ohio State University), William Blum(The Ohio State University), Don M. Benson(The Ohio State University), Natarajan Muthusamy(Manonmaniam Sundaranar University)
Cited by 22
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718